San Francisco: The COVID-19 pandemic could extend till 2024 as the lower-dose version of its vaccine for 2-4 years olds generated a weaker immune response than expected, Pfizer Inc said on Friday.
Pfizer has developed the vaccine with Germany’s BioNTech SE. While a 3-microgram dose of its vaccine was tested on 2-5 year-olds, a 10-microgram dose was used in 5-11 year-olds and 30-microgram doses in everyone over 12. In children aged 6 to 24 months, the low-dose version of the vaccine generated an immune response consistent with that of older vaccine recipients, Reuters reported.
The company said it had expected data of its testing of three-dose course of the vaccine in all age groups under 16, including 2-4-year-olds, this year. Despite the delay, it would go ahead and file for emergency use authorization in the second quarter of 2022.
“The data are illustrating the impact of a booster and that our vaccine works best as a primary regimen of three doses,” Pfizer chief scientific officer Mikael Dolsten said on a conference call.
Mumbai: Television actor Nitin Chauhan’s untimely demise at the age of 35 has once again…
Cuttack: Vendors will not be allowed to do business on footpaths during the upcoming Bali…
Mumbai: Sandeep Pattanaik completed a fighting century but that didn’t help Odisha avoid a follow-on…
Bhubaneswar: After several Biju Janata Dal (BJD) leaders blamed VK Pandian for the regional party’s…
Mumbai: The Congress-National Conference (NC) alliance which formed the government in Jammu & Kashmir after winning…
New Delhi: It was the last day in office for Dhananjaya Yeshwant Chandrachud as Chief…
Cuttack: The Orissa High Court has refused to quash a criminal case against a lawyer…
Bhubaneswar: The cyclonic circulation over southwest Bay of Bengal is likely to intensify into a…